Nanopore Sequencing for Accelerating Breast Cancer Diagnosis in Tanzania: A Prospective Observational Study
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This pilot study will test the feasibility of using nanopore sequencing for breast cancer diagnosis in Tanzania. It aims to show that nanopore sequencing is non-inferior to the current standard of care, with the potential for faster and more cost-efficient results. By enhancing the speed and accuracy of diagnosis, this approach could improve treatment planning and outcomes for patients in resource-limited settings.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patient with suspected diagnosis of breast cancer undergoing biopsy or surgical resection after specialist consultation as per institutional guidelines
• Excess fresh tumor sample
• Written informed consent
Locations
Other Locations
United Republic of Tanzania
Kilimanjaro Christian Medical Centre
RECRUITING
Moshi
Contact Information
Primary
Oliver Henke, MD
Oliver.Henke@ukbonn.de
+49 (0) 228 287 51521
Backup
Maximilian Rost, MD
maximilian.rost@ukbonn.de
+49 (0) 228 287 51521
Time Frame
Start Date: 2025-05
Estimated Completion Date: 2026-05
Participants
Target number of participants: 100
Treatments
Nanopore sequencing
All adult patients at with suspected diagnosis of breast cancer undergoing biopsy or surgical resection will be offered to participate in the study. After informed written consent excess tissue is preserved for DNA extraction using commercial spin column kits and will be further analyzed.
Related Therapeutic Areas
Sponsors
Collaborators: German Cancer Research Center, Kilimanjaro Christian Medical Centre,Moshi,Tanzania
Leads: University of Bonn